Kenvue Inc. (NYSE:KVUE) Shares Sold by Foundry Partners LLC

Foundry Partners LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 10.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 492,848 shares of the company’s stock after selling 56,455 shares during the quarter. Foundry Partners LLC’s holdings in Kenvue were worth $10,611,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of KVUE. Clearstead Advisors LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue during the fourth quarter valued at approximately $27,000. AdvisorNet Financial Inc purchased a new position in shares of Kenvue during the third quarter valued at approximately $28,000. Global Retirement Partners LLC purchased a new position in shares of Kenvue during the third quarter valued at approximately $28,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Kenvue during the third quarter valued at approximately $28,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE remained flat at $19.58 during midday trading on Friday. 9,506,274 shares of the stock traded hands, compared to its average volume of 12,499,857. The firm has a 50 day moving average price of $19.84 and a 200 day moving average price of $20.16. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business’s revenue was down 2.7% compared to the same quarter last year. Equities analysts expect that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date was Tuesday, February 13th.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. Royal Bank of Canada cut their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. Finally, The Goldman Sachs Group started coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.